Form 8-K Filing: Royalty Pharma plc - Officer Transition

Royalty Pharma plc announced a change in its executive leadership. George W. Lloyd, Executive Vice President and Chief Legal Officer, will transition from his role effective December 31, 2025. He will remain with the company as a senior advisor. Arthur R. McGivern, Executive Vice President and General Counsel, will assume Mr. Lloyd's responsibilities starting January 1, 2026. Mr. McGivern, who joined the company in October 2022, was previously a partner at Goodwin Procter LLP. The Executive Offer Letter between Mr. Lloyd and the Company, dated May 16, 2025, will be terminated effective December 31, 2025. Mr. Lloyd will then enter into the Company's standard form employee offer letter.